1. Brief Report {#sec0001}
===============

In early Dec 2019, reports of Coronavirus Disease 2019 (COVID-19) patients first emerged in Wuhan, China [@bib0001]. On 23th Jan 2020, Singapore\'s first reported case of COVID-19 in Singapore was identified at the Singapore General Hospital [@bib0002]. Since then, the Ministry of Health, Singapore, quickly raised "Disease Outbreak Response System Condition" (DORSCON) alert to orange (the second highest level of alert) on 7th Feb 2020, and implemented various measures nationwide, including border control, quarantine of contacts of COVID-19 cases or those who have travelled to affected areas, temperature screening as well as restricting the number of visitors to the hospital. As of 26^th^ July 2020, Singapore has had 50, 369 confirmed cases [@bib0001].

In light of increasing COVID-19 cases locally and internationally [@bib0002], our hospital faced competing manpower needs arising from health crisis management, leading to uncertainty over manpower allocation of non-direct patient care personnel e.g. antibiotic stewardship practitioners. Here, we aim to describe the impact of COVID-19 on antibiotic use and the role of Antibiotic Stewardship Program (ASP) in Singapore General Hospital (SGH), an 1800-bed, tertiary-care hospital. Our multidisciplinary ASP comprises of 9 trained infectious diseases pharmacists, as well as 3 infectious disease (ID) physicians. The pharmacy team performs daily audits electronically, of selected broad-spectrum antibiotic prescriptions (carbapenems, piperacillin-tazobactam, ciprofloxacin and levofloxacin) for appropriateness, in terms of indication, route, duration and choice and intervenes where appropriate; the audited prescriptions of more complex cases are reviewed daily with the attending ID physician who is rostered for the day [@bib0003].

When Singapore raised the DORSCON alert to orange, our institution mandated cancellation of elective and non-urgent procedures / surgeries, to ring-fence more beds for dedicated respiratory and pneumonia wards in preparation for larger scale outbreak. Negative pressure rooms in our hospital are solely used for COVID-19 suspects and cases. Operationally, face-to-face meetings were discouraged within the institution and the workforce was generally divided into small teams (e.g. 5-10 members per team), as part of the hospital\'s business contingency plan. Accordingly, our ASP team was divided into two pharmacy teams so that ASP would still be operationally functional with one team if the other team had to be quarantined. In place of face-to-face meetings, daily ASP meetings with the ID physician were conducted via teleconferencing.

The first COVID-19 case was reported in Singapore on the 23^rd^ Jan 2020, and as the number of cases increased, a stay-at-home order and *cordon sanitaire* termed "circuit breaker" was implemented as a preventative measure on the 7^th^ Apr 2020 [@bib0002]. For the purpose of this letter, we compared antibiotic use pre-COVID-19 (1^st^ Feb -- 30^th^ Apr 2019) and during the acceleration phase of the COVID-19 pandemic (1^st^ Feb -- 30^th^ Apr 2020).

During the designated COVID-19 period, our hospital saw a 16.8% year-on-year reduction in the overall number of hospital admissions (from 19, 589 to 16, 300); bed occupancy was also reduced from 130, 597 bed-days pre-COVID-19 to 113, 449 bed-days during COVID-19. Yet, there was a 25.5% increase in the utilization of broad-spectrum antibiotics such as cefepime, piperacillin/tazobactam, carbapenems and vancomycin where defined daily doses (DDD) rose from 14.92 DDD per 100 bed-days to 18.72 DDD per 100 bed-days. Similarly, the utilization of antibiotics for the treatment of community-onset pneumonia increased from 48.74 DDD per 100 bed-days to 50.81 DDD per bed-days. This increase was most marked in Feb 2020 during the onset of the COVID-19 pandemic, with a notable rise in month on month DDD of ceftriaxone, co-amoxiclav, levofloxacin, moxifloxacin, azithromycin and clarithromycin from 47.4 DDD per 100 bed-days to 54.0 DDD per 100 bed-days (See [Figure 1](#fig0001){ref-type="fig"} ). The average monthly proportion of patients on antibiotics was also correspondingly higher (47.4% vs 49.9%) during the COVID-19 pandemic for the same period of time the year before, with the highest proportion documented at the onset. (See [Figure 2](#fig0002){ref-type="fig"} ). However, as the pandemic evolved, antibiotic use gradually declined, and we attribute this to (a) an increased understanding of COVID-19 as international data emerged, and medical teams were more judicious with antibiotic use thereafter (per communication with Dr. SJ Chung), (b) further restrictions in elective admissions with implementation of "circuit breaker" measures in Apr 2020, and (c) a change in demographics of admissions for respiratory viral illness, where a significant proportion were young able bodied foreign dormitory workers with mild COVID-19, who were paucisymptomatic or asymptomatic [@bib0001], and antibiotics were not prescribed in this group of patients.Figure 1**Comparison of the consumption of antibiotics used for the treatment of community-onset pneumonia pre-COVID-19 and during COVID-19**. Defined daily doses (DDD) of antibiotics (ceftriaxone, co-amoxiclav, levofloxacin, moxifloxacin, azithromycin and clarithromycin) were higher for the months of Feb and Mar during the onset of the COVID-19 pandemic.Figure 1Figure 2**Proportion of patients on antibiotics pre-COVID-19 and during COVID-19**. The proportion of patients on antibiotics in 2019 (pre-COVID-19) are represented by the blue line, and on average, approximately 48% of hospitalized patients are on antibiotics in 2019. For the months of Jan to Mar 2020 (during the COVID-19 pandemic), antibiotic use was proportionately higher.Figure 2

Interestingly, ASP\'s workload was maintained despite lower admission numbers and bed occupancy. We performed 2, 542 audits pre-COVID-19 and 2, 689 audits during the COVID-19 period. The details and clinical impact of our ASP interventions are detailed in [Table 1](#tbl0001){ref-type="table"} . In essence, there was no significant difference in intervention acceptance rates between both groups. The impact of ASP interventions was sustained during the COVID-19 period with significant reduction in duration of antibiotic therapy, and reduced length of stay in cases where ASP interventions were accepted. Such beneficial outcomes potentially alleviate the problem of bed crunch during the pandemic.Table 1Comparison of ASP interventions and outcomes Pre -- COVID -19 (1st Feb to 30th Apr 2019) and during the acceleration phase of the COVID -- 19 pandemic (1st Feb to 30th Apr 2020)Table 1Types of interventionsPre -- COVID-19[a](#tb1fn1){ref-type="table-fn"}, n (%)COVID-19[b](#tb1fn2){ref-type="table-fn"}, n (%)*P* valueN = 560N = 578**ASP Acceptance**470 (83.9)488 (84.4)0.89*[Type of ASP interventions]{.ul}***Broaden empirical coverage**6 (1.1)9 (1.6)0.87**Narrow empirical coverage**102 (18.2)102 (17.6)1.00**Revision of antibiotics based on culture data**89 (15.9)73 (12.6)1.00**Discontinuation of antibiotics**217 (38.8)181 (31.3)0.69**IV to PO switch**64 (11.4)79 (13.7)0.49**Optimization of antibiotic doses**24 (4.3)71 (12.3)0.56**Trigger ID consult or ID review**35 (6.3)30 (5.2)0.11**Additional recommendations**[c](#tb1fn3){ref-type="table-fn"}23 (4.1)33 (5.7)0.70***Impact of ASP interventions*AcceptedRejectedP valueAcceptedRejectedP value**Median duration of antibiotic therapy (IQR), in days3 (2 - 5)6 (4 -- 10)\<0.05\*\*4 (2-4)8 (3.0 -- 9)\<0.05\*\*Median LOS post ASP intervention (IQR), in days6 (2-15)7 (4-11)0.537 (4-16)12 (7-28)\< 0.01\*\*[^1][^2][^3][^4][^5]

This epidemic has placed enormous strain on healthcare providers and healthcare systems worldwide. Locally, our country has placed a high emphasis on identifying and isolating COVID-19 patients in our bid to contain the spread of the virus. In the early weeks of our containment strategy, patients with signs and symptoms suggestive of viral illness were actively screened and isolated until results return negative for COVID-19. Consequently, we perceived that there were more admissions of patients with acute respiratory illness, which would otherwise have been treated in the community in prior to the COVID-19 pandemic. These patients were usually started empirically on antibiotics used for the treatment of community-onset pneumonia coinciding with the increased utilization of these agents. Furthermore, our initial hypothesis that the use of broad-spectrum antibiotics should drop together with the admission numbers was debunked. Instead, prescription numbers for these agents were observed to increase as they target serious, nosocomial infections which are often associated with urgent conditions (e.g. cancer for which treatment cannot be delayed). Hence, in a tertiary healthcare institution like ours, the impact of COVID-19 as well as the continued care for hospitalized patient with complex medical issues, culminated in the higher proportion of patients on antibiotics compared to pre-COVID period. It would be prudent to maintain the ASP even in viral epidemics / pandemics with existing manpower support [@bib0004].

At the start of the pandemic, we received support from hospital management to maintain the ASP as an essential service, a commitment towards our continued fight against antimicrobial resistance. We also learnt the importance for ASPs to be operationally adaptable to different scenarios. Organizational restructuring and migration to telecommuting platforms for our ASP activities was crucial for maintaining our clinical service while observing distancing measures, thus ensuring patient and staff safety in this pandemic. We also realized that in addition to focusing our efforts on nosocomial treatments, this is an opportunity for our team to execute a syndromic approach towards guiding antibiotic prescribing for respiratory tract infections. To do so, we must employ digital platforms and continue to develop robust surveillance systems that are able to detect subtle changes in prescribing and resistance trends. What is also important in outbreak situations like these is on-going engagement and education of prescribers to mitigate antibiotic misuse that tends to occur with viral epidemics / pandemics, undoing years of progress in antibiotic stewardship.

Given that we are engaged in this COVID-19 battle for a long haul, the role of ASP is vital to ensuring the quality of our antibiotic use is upheld because the problem of antibiotic resistance remains in the long term [@bib0005].

The Singhealth Centralised Institutional Review Board approved this retrospective review of our service. Informed consent was not obtained from individual patients as the operations of the ASP constituted routine clinical practice and only anonymized data were analyzed.
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[^1]: \*\* p \<0.05 statistically significant.

[^2]: *Abbreviations:* IV, intravenous; PO, per oral; IQR, interquartile range; LOS, length of stay.

[^3]: Pre-COVID-19: This refers to the period was between 1^st^ Feb -- 30^th^ Apr 2019.

[^4]: COVID-19: This refers to the period was between 1^st^ Feb -- 30^th^ Apr 2020.

[^5]: Recommendations for diagnostic investigations and/or infection control precautions were made to guide management of the infectious diseases' issues.
